Comparison of recombinant human thrombin and plasma-derived human α-thrombin

Seminars in Thrombosis and Hemostasis

Volumn 32, Issue SUPPL. 1, 2006, Pages 86-97

  Bishop, Paul D ^a   Lewis, Kenneth B ^a   Schultz, Jody ^a   Walker, Kathleen M ^a  

^a ZYMOGENETICS INC   (United States)

Author keywords

Prethrombin; Prothrombin; rhThrombin

Indexed keywords

ALPHA THROMBIN VARIANT; BETA THROMBIN; CROSS REACTING ANTIBODY; HIRUDIN; PLASMA DERIVED ALPHA THROMBIN; PRETHROMBIN 1; PROTEIN PRECURSOR; RECOMBINANT THROMBIN; THROMBIN; UNCLASSIFIED DRUG;

ANIMAL CELL; BLEEDING; BLOOD CLOTTING; CHO CELL; CONTROLLED STUDY; DRUG POTENCY; ENZYME ACTIVITY; EXCISION; FIBRIN FORMATION; HEMOSTASIS; HUMAN; HUMAN CELL; IN VIVO STUDY; INTERMETHOD COMPARISON; NONHUMAN; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; RABBIT; REVIEW; RISK ASSESSMENT; THROMBOCYTE ACTIVATION;

ANIMALS; BLOOD LOSS, SURGICAL; HUMANS; MOLECULAR WEIGHT; QUALITY CONTROL; RECOMBINANT PROTEINS; THROMBIN;

EID: 33646489465     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-939558     Document Type: Review

References (18)

1. Hedner U. Mechanism of action of factor VIIa in the treatment of coagulopathies. Semin Thromb Hemost 2006; 32(suppl 1):77-85
2. Roberts H, Hoffman M, Monroe D. A cell-based model of thrombin generation. Semin Thromb Hemost 2006;32(suppl 1):32-38
3. Schoenecker JG, Hauck RK, Mercer MC, Parker W, Lawson JH. Exposure to topical bovine thrombin during surgery elicits a response against the xenogeneic carbohydrate galactose alpha1-3galactose. J Clin Immunol 2000;20:434-444
4. Bishop P, Lawson J. Recombinant biologics for treatment of bleeding disorders. Nat Rev Drug Discov 2004;3:684-694
5. Ortel TL, Mercer MC, Thames EH, Moore KD, Lawson JH. Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin. Ann Surg 2001;233:88-96
6. Winterbottom N, Kuo JM, Nguyen K, et al. Antigenic responses to bovine thrombin exposure during surgery: a prospective study of 309 patients. J Appl Res 2002;2:1-11
7. Lawson J. The clinical use and immunologic impact of thrombin in surgery. Semin Thromb Hemost 2006;32 (suppl 1):98-110
8. Franchini M, Zaffanello M, Veneri D. Recombinant factor VIIa. An update on its clinical use. Thromb Haemost 2005; 93:1027-1035
9. Pipe SW. The promise and challenges of bioengineered recombinant clotting factors. J Thromb Haemost 2005;3:1692-1701
10. Blostein MD, Furie BC, Rajotte I, Furie B. The Gla domain of factor IXa binds to factor Villa in the tenase complex. J Biol Chem 2003;278:31297-31302
11. Sugiura T, Maruyama HB. Factors influencing expression and post-translational modification of recombinant protein C. J Biotechnol 1992;22:353-360
12. Bendig MM. The production of foreign proteins in mammalian cells. Genet Eng 1988;7:91-127
13. Jenny N, Mann K. Thrombin. In: Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia, PA: Lippincott Williams & Wilkins; 2001
14. Liu LW, Vu TK, Esmon CT, Coughlin SR. The region of the thrombin receptor resembling hirudin binds to thrombin and alters enzyme specificity. J Biol Chem 1991;266:16977-16980
15. Möller TP, Weinstein JR, Hanisch U-K. Activation of microglial cells by thrombin: past, present, and future. Semin Thromb Hemost 2006;32(suppl 1):69-76
16. Whitton C, Sands D, Lee T, Chang A, Longstaff C. A reunification of the US ("NIH") and International Unit into a single standard for thrombin. Thromb Haemost 2005;93:261-266
17. Sonder SA, Fenton JW. Thrombin specificity with tripeptide chromogenic substrates: comparison of human and bovine thrombins with and without fibrinogen clotting activities. Clin Chem 1986;32:934-937
18. Hemker HC, Beguin S. Thrombin generation in plasma: its assessment via the endogenous thrombin potential. Thromb Haemost 1995;74:134-138